Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Synonyms :
Class :
Acute Lymphoblastic Leukemia(All)Â
For the Patients on a cytarabine-containing regimen who are not responding to induction therapy:
Administer 165 mg/m2 intravenously at a minimum half-hour to 1-hour duration & administer cytarabine 300 mg/m2 intravenously two times a week in 8-9 doses
For Individuals unresponsive to regimens involving prednisone & vincristine:
Intravenous administration of 250 mg/m2 for a minimum of half-hour to 1-hour duration & administer prednisone in the dose of 40 mg/m2 for the duration of twenty-eight days through oral route with the administration of vincristine 1.5 mg/m2 intravenously in a week for the duration of four to eight weeks
Acute Lymphoblastic Leukemia(All)Â
For the Patients on a cytarabine-containing regimen who are not responding to induction therapy (for 14 days & more)
Administer 165 mg/m2 intravenously at a minimum half-hour to 1-hour duration & administer cytarabine 300 mg/m2 intravenously two times a week in 8-9 doses
For Individuals unresponsive to regimens involving prednisone & vincristine: (for 14 days & more)
Intravenous administration of 250 mg/m2 for a minimum of half-hour to 1-hour duration & administer prednisone in the dose of 40 mg/m2 for duration of twenty-eight days through oral route with the administration of vincristine 1.5 mg/m2 intravenously in a week for the duration of four to eight weeks
CYP3A strong enhancers of the small intestine may reduce the bioavailability of teniposide
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
nafcillin will decrease the effect of action of teniposide by affecting enzyme CYP3A4 metabolism.
when both drugs are combined, there may be a decreased metabolism of etoposide   
when both drugs are combined, there may be an increased risk or severity of adverse effects  
the effect of teniposide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may enhance the serum concentration of P-glycoprotein/ABCB1 inhibitors
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may enhance the serum concentration of P-glycoprotein/ABCB1 Inhibitors
when both drugs are combined, there may be an increased metabolism of teniposide